Ophthalmic components
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- LION CORP
- Filing Date
- 2025-12-11
- Publication Date
- 2026-06-25
AI Technical Summary
【0009】 本発明によれば、水晶体の弾性の低下に伴う、又は眼の調節機能の低下に伴う、眼症状又は眼疾患の予防、改善又は治療用の眼科組成物を提供することができ、ピント調節機能の予防、改善又は治療用、老視の予防、改善又は治療用として好適である。
Smart Images
Figure 2026104840000001 
Figure 2026104840000002 
Figure 2026104840000003
Abstract
Claims
1. An ophthalmic composition for the prevention, improvement, or treatment of ophthalmic symptoms or eye diseases associated with a decrease in the elasticity of the lens, comprising glycyrrhizic acid or a pharmaceutically acceptable salt thereof (A) as an active ingredient.
2. An ophthalmic composition for the prevention, improvement, or treatment of ophthalmic symptoms or diseases associated with a decline in the eye's accommodative function, comprising glycyrrhizic acid or a pharmaceutically acceptable salt thereof (A) as an active ingredient.
3. The ophthalmic composition for prevention, improvement, or treatment according to claim 1 or 2, wherein the aforementioned ophthalmic symptoms or ophthalmic disease are presbyopia.
4. The ophthalmic composition for prevention, improvement, or treatment according to claim 1 or 2, wherein the aforementioned ophthalmic symptoms or ophthalmic disease are ophthalmic symptoms or ophthalmic diseases associated with a decrease in the ability to focus.
5. The ophthalmic composition for prevention, improvement, or treatment according to claim 4, wherein the aforementioned ophthalmic symptoms or ophthalmic disease are presbyopia.
6. An ophthalmic composition for the prevention, improvement, or treatment of presbyopia, comprising glycyrrhizic acid or a pharmaceutically acceptable salt thereof (A) as an active ingredient.
7. The ophthalmic composition according to claim 1, 2, or 6, wherein the content of component (A) is 0.0001 to 10% (w / v%) in the ophthalmic composition.
8. The ophthalmic composition according to claim 1, 2, or 6, wherein component (A) is selected from glycyrrhizic acid, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, and trisodium glycyrrhizinate.
9. Furthermore, the ophthalmic composition according to claim 1, 2, or 6 further contains one or more selected from drugs other than component (A), polyhydric alcohols, surfactants, sugars, buffers, pH adjusters, isotonic agents, stabilizers, cooling agents, viscosity enhancers, preservatives, and oil components, and water.
10. The ophthalmic composition according to claim 1, 2, or 6, further comprising one or more (B) selected from dibutylhydroxytoluene, vitamin E and its pharmaceutically acceptable derivatives, and allantoin.
11. The ophthalmic composition according to claim 10, wherein component (B) is d-α-tocopherol acetate.
12. The ophthalmic composition according to claim 10, further comprising one or more selected from drugs other than component (A) and component (B), polyhydric alcohols, surfactants, sugars, buffers, pH adjusters, isotonic agents, stabilizers, cooling agents, viscosity enhancers, preservatives, and oil components, and water.